Click here - to use the wp menu builder

BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

SAN DIEGO & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $BGNE #BGNE–BeiGene will hold an exclusive license to the global clinical development and commercialization of BioAtla’s investigational CAB CTLA-4 antibody.

Source

BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

Recent Articles

Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency

Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience

U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C

New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People...

Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia